Compare AbbVie Inc (ABBV) vs Funko Inc (FNKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Funko Inc — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Funko Inc trades at $5.28 (market cap $301.53M). The key difference: AbbVie Inc is far larger — about 1492.1× Funko Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| ABBV | FNKO | |
|---|---|---|
Market Cap | $449.91B | $301.53M |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $5.88 |
52-Week Low | $184.85 | $2.46 |
Enterprise Value | $513.38B | $546.57M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
FNKO trades at $5.40, down 2.0% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth to $200.9M, beating EPS estimates, though net income remains negative. Analyst sentiment is mixed with 42.9% buy ratings, while recent news highlights strong product launches and management changes.
The outlook is cautiously optimistic given earnings beats and revenue stabilization, but profitability challenges and negative margins pose risks. Investment opportunity lies in operational turnaround and brand strength, balanced against high debt and competitive pressures in the collectibles market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
